Bridger Management LLC Makes New $5.70 Million Investment in Eli Lilly and Company $LLY

Bridger Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 7,307 shares of the company’s stock, valued at approximately $5,696,000. Eli Lilly and Company makes up approximately 3.4% of Bridger Management LLC’s portfolio, making the stock its 15th largest holding.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Perennial Investment Advisors LLC boosted its position in Eli Lilly and Company by 3.1% during the second quarter. Perennial Investment Advisors LLC now owns 1,868 shares of the company’s stock valued at $1,456,000 after purchasing an additional 57 shares during the last quarter. PFG Private Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 5.3% during the 2nd quarter. PFG Private Wealth Management LLC now owns 457 shares of the company’s stock worth $356,000 after purchasing an additional 23 shares in the last quarter. Semus Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 9.0% in the 2nd quarter. Semus Wealth Partners LLC now owns 4,003 shares of the company’s stock valued at $3,120,000 after buying an additional 332 shares during the last quarter. Bedell Frazier Investment Counselling LLC grew its stake in shares of Eli Lilly and Company by 126.8% in the second quarter. Bedell Frazier Investment Counselling LLC now owns 9,641 shares of the company’s stock valued at $7,515,000 after buying an additional 5,390 shares in the last quarter. Finally, United Advisor Group LLC increased its holdings in Eli Lilly and Company by 47.9% during the second quarter. United Advisor Group LLC now owns 806 shares of the company’s stock worth $628,000 after buying an additional 261 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,015.11.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,023.32 on Tuesday. The stock has a market cap of $967.43 billion, a P/E ratio of 66.88, a PEG ratio of 1.21 and a beta of 0.43. The stock has a 50 day simple moving average of $832.59 and a 200 day simple moving average of $780.91. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.